Explore Brainstorm Cell Therapeutics' Q1 2025 earnings call highlights, including FDA clearance for their ALS Phase 3b trial, funding efforts, ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, ...

Chaim Lebovits; President, Chief Executive Officer; Brainstorm Cell Therapeutics Inc. Hartoun Hartounian; Chief Operating Officer, Executive Vice President; Brainstorm Cell Therapeutics Inc. Ibrahim ...

Decades of feedback and design improvements have shaped the Safariland Ballast’s functionality. Ballast’s lightweight and ...

Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading ...

Planetary Design in Bonner is hosting the Pedals vs. ALS event, a stop on Timm Fenton's cross-country bike journey.

BrainStorm Cell Therapeutics saw rising retail chatter Monday when it obtained FDA clearance for Phase 3b clinical trials of ...

Manufacturing companies have been automating processes and utilising robotics for decades. But when it comes to the use of ...

FDA clearance and strategic partnerships position Brainstorm Cell Therapeutics Inc (BCLI) for a significant milestone in ALS research, despite financial hurdles.

Neighborhoods near golf courses are often considered desirable locations, blending nature, leisure and nice views. However, a ...

Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS and ...